falsefalse

Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 13

45-Year-Old Never-Smoker with Advanced EGFR-Mutant NSCLC and CNS Metastases Treated with the MARIPOSA Regimen

,

Panelists discuss how a 45-year-old anxious patient who refused chemotherapy was successfully treated with amivantamab plus lazertinib along with prophylactic management strategies for potential adverse effects.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Case Presentation 2 – Patient With Treatment Preferences

    Main Discussion Topics:

    • Management of a 45-year-old preschool teacher with significant anxiety about treatment
    • Addressing a patient’s strong preference against chemotherapy
    • Implementation of prophylactic strategies for adverse event management

    Key Points for Physicians:

    • Patient with EGFR exon 21 mutation, numerous brain metastases, and adamant preference against chemotherapy
    • Amivantamab + lazertinib selected as a chemotherapy-free option with demonstrated overall survival and central nervous system (CNS) benefits
    • Comprehensive prophylactic measures implemented (dexamethasone premedication, skin prophylaxis, anticoagulation)

    Notable Insights:

    Patient education involved balancing data-driven information about efficacy with counseling about expected toxicities and management strategies.

    Clinical Significance:

    This case demonstrates how treatment selection can be successfully tailored to align with patient preferences while still providing optimal efficacy for high-risk disease features.

    x